| |
| Date |
Type |
Title |
|
Feb 13, 2006 |
Article |
Melatonin May Help Cut Hypertension?
Melatonin, a naturally occurring hormone that can be taken orally to regulate sleep patterns, reduced the blood pressure (BP) of hypertensive women, claim Italian researchers. |
|
Jan 20, 2006 |
Abstract |
Abstract: Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit
Because NADH increases cellular production of ATP and facilitates dopamine synthesis, it may counteract the effects of jet lag on cognitive functioning and sleepiness. |
|
Jan 02, 2006 |
Article |
Beat the Sneezin' Season Naturally
Taking a stand against cold and flu season for you and your family is easier than you think. Woodson Merrell, MD, explains how to break the sickness cycle by taking protective measures and boosting immunity. |
|
Oct 03, 2005 |
Article |
Lyme Disease and Its Link to Fibromyalgia, Chronic Fatigue and Immune Dysfunction Syndrome and Unrelenting Fatigue
According to Dr. Kent Holtorf, "Patients suffering with a chronic illness -- and especially those with Fibromyalgia, Chronic Fatigue and Immune Dysfunction Syndrome and Unrelenting Fatigue -- should consider Lyme disease as a contributor." |
|
Oct 03, 2005 |
Article |
Lyme Disease and Its Link to Fibromyalgia, Chronic Fatigue and Immune Dysfunction Syndrome and Unrelenting Fatigue
According to Dr. Kent Holtorf, "Patients suffering with a chronic illness -- and especially those with Fibromyalgia, Chronic Fatigue and Immune Dysfunction Syndrome and Unrelenting Fatigue -- should consider Lyme disease as a contributor." |
|
Sep 07, 2005 |
DrugNews |
AMBIEN CR(TM) (Zolpidem Tartrate Extended-Release Tablets) CIV Receives FDA Approval for the Treatment of Insomnia
Sanofi-aventis (NYSE: SNY; EURONEXT: SAN) announced today that the U.S. Food and Drug Administration (FDA) has approved AMBIEN CR(TM) (zolpidem tartrate extended-release tablets) CIV, a new extended-release formulation of the number one prescription sleep aid, AMBIEN(R) (zolpidem tartrate) CIV, for the treatment of insomnia. |
|
Aug 29, 2005 |
Article |
Mood Lighting: Penn Researchers Determine Role of Serotonin in Modulating Circadian Rhythm
The body’s 24-hour (circadian) clock controls cycles of wakefulness and sleep, as well as the rhythm of other physiological functions, such as body temperature and blood pressure. Although the body functions on roughly a 24-hour schedule, this cycle is capable of being reset by environmental disturbances. |
|
Jun 06, 2005 |
Article |
Myth That Exercise and Arthritis Don't Mix Still Lingers
"For years, people with arthritis thought the right answer was to avoid activity, physical therapy and exercise, for fear that their pain would get worse. Well, avoiding activity and exercise is actually the wrong answer," says Vert Mooney, M.D., an orthopedic spine surgeon in San Diego, CA. |
|
Apr 25, 2005 |
Article |
The Sleep-Wake Body Clock May Also Control Appetite
Our molecular body clock may also play a role in regulating appetite, researchers report, in a finding that could someday be used to help compulsive eaters slim down. |
|
Apr 06, 2005 |
Article,DrugNews |
Sepracor Announces Launch Timing for LUNESTA(TM) Brand Eszopiclone for Treatment of Insomnia
The U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for LUNESTA on December 15, 2004. Data from a landmark, long-term (six-month), double-blind, placebo-controlled safety and efficacy study in 788 patients were reviewed by the FDA as part of the NDA submission for eszopiclone and served as a basis for the FDA's decision to approve LUNESTA for long-term use. |
|
|
Next 10 Articles>> |
|
|
|
|
